Eli Lilly drug shows significant results in slowing Alzheimerâs
The experimental drug, donanemab, was studied at two R.I. hospitals
By Alexa Gagosz Globe Staff,Updated March 15, 2021, 2:32 p.m.
Email to a Friend
Dr. Stephen Salloway is the director of the Memory and Aging Program at Butler Hospital, where he led the TRAILBLAZER study. He is also a professor of psychiatry and human behavior and of neurology at Brown Universityâs Warren Alpert Medical School.Nick Dentamaro/Brown University
PROVIDENCE â Rhode Island is once again playing a critical role in the development of promising potential treatments for Alzheimerâs disease.
Endovascular Approach to Diabetic Limb Ischemia Tied to Lower Hospital Mortality, More Amputations medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
PROVIDENCE – A new investigational drug has demonstrated a significant reduction in cognitive deficits in people who are living in the early stages of Alzheimer’s disease, researchers at Butler and Rhode Island hospitals and Brown University have reported in the New England Journal of Medicine.
The drug, donanemab, from pharmaceutical firm Eli Lilly and Company, targets the amyloid plaque and tau protein build-ups in the brain that are associated with the development of Alzheimer’s and other types of dementia.
“This is yet another significant and encouraging milestone in what has proven to be a momentous year in the fight against Alzheimer’s disease,” said Dr. Stephen P. Salloway, one of the paper’s authors and head of Butler’s Memory and Aging Program. “In the last twelve months, we’ve seen significant advancements in diagnosing and treating Alzheimer’s.”
A Tattoo on my Brain
A Tattoo on my Brain
A Tattoo on my Brain
A Neurologist s Personal Battle against Alzheimer s Disease
Search within full text
Publisher:
Cambridge University Press
Print publication year:
2021
A Tattoo on my Brain
Who would you like to send this to
Optional message
Book description
Dr Daniel Gibbs is one of 50 million people worldwide with an Alzheimer s disease diagnosis. Unlike most patients with Alzheimer s, however, Dr Gibbs worked as a neurologist for twenty-five years, caring for patients with the very disease now affecting him. Also unusual is that Dr Gibbs had begun to suspect he had Alzheimer s several years before any official diagnosis could be made. Forewarned by genetic testing showing he carried alleles that increased the risk of developing the disease, he noticed symptoms of mild cognitive impairment long before any tests would have alerted him. In this highly personal account, Dr Gibbs documents the effect his diagnosis has ha
Dr. Stephen Salloway. Photo: Brown/CNE
Butler Hospital in Providence announced on Monday that clinical trial results announced over the weekend and published in the New England Journal of Medicine (NEJM) indicate that the investigational drug donanemab holds promise as a potential treatment for early Alzheimer s disease.
Stephen Salloway, MD, MS, Director of the Memory and Aging Program and of Neurology at Butler Hospital and the Martin M. Zucker Professor of Psychiatry and Human Behavior and professor of Neurology at the Warren Alpert Medical School of Brown University, is a co-author of the NEJM article. GET THE LATEST BREAKING NEWS HERE SIGN UP FOR GOLOCAL FREE DAILY EBLAST